open access: Clinical Benefit and Toxicity of Continuing Bevacizumab Containing Chemotherapies in Patients with Recurrent Ovarian Cancer

Blogger's Note: small study

Clinical Benefit and Toxicity of ContinuingBevacizumab Containing Chemotherapies inPatients with Recurrent Ovarian Cancer

"...In conclusion, community practice has adopted
a strategy of bevacizumab administration in combination
with various cytotoxic chemotherapy agents under
various schedules, and continuation of bevacizumab use
after initial disease progression or toxicity to
bevacizumab's partner chemotherapy. Our study showed
that such an approach is relatively safe and potentially
beneficial. We did not notice any cases of major
toxicities such as GI perforation or arterial thrombosis;
however, new development of hypertension was
common and at times severe, particularly in elderly
patients. The theme of continuing VEGF inhibitor
treatment in refractory ovarian cancer at the time of
disease progression warrants large scale prospective
study."